Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers
NCT00002515Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 1992
- Primary completion
- Apr 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, carboplatin and topotecan in rare cancer, Wilms' tumor, liver cancer and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Disease-Free Survival at 1 year. Started Oct 1992; status: completed.
02
Drugs
thiotepacarboplatintopotecan
03
Conditions
rare cancerWilms' tumorliver cancerdesmoplastic small round cell tumor (DSRCT)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00002515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002515.